Tocotrienol-Rich Vitamin E (Tocovid) Improved Nerve Conduction Velocity in Type 2 Diabetes Mellitus Patients in a Phase II Double-Blind, Randomized Controlled Clinical Trial

Autor: Yan Yi Koay, Nevein Philip Botross Henien, Sonia Chew Wen Phang, J-Ian Ho, Yeek Tat Ng, Pei Fen Chuar, Badariah Ahmad, Khalid Abdul Kadir, Loon Shin Ho
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Male
Vascular Endothelial Growth Factor A
medicine.medical_specialty
Population
Urology
Neural Conduction
transforming growth factor beta-1 (TGFβ-1)
Motor nerve
Sural nerve
vitamin E
Nerve conduction velocity
Article
Transforming Growth Factor beta1
Diabetic Neuropathies
Double-Blind Method
Sural Nerve
medicine
Humans
TX341-641
tocotrienol
education
Aged
Motor Neurons
education.field_of_study
Nutrition and Dietetics
medicine.diagnostic_test
Tibia
business.industry
Nutrition. Foods and food supply
Tocotrienols
diabetic peripheral neuropathy
type 2 diabetes mellitus (T2DM)
Middle Aged
vascular endothelial growth factor A (VEGF-A)
medicine.disease
Median nerve
Median Nerve
medicine.anatomical_structure
Peripheral neuropathy
Treatment Outcome
Diabetes Mellitus
Type 2
Dietary Supplements
Nerve conduction study
Female
business
Biomarkers
Food Science
Sensory nerve
Zdroj: Nutrients
Volume 13
Issue 11
Nutrients, Vol 13, Iss 3770, p 3770 (2021)
ISSN: 2072-6643
DOI: 10.3390/nu13113770
Popis: Diabetic peripheral neuropathy (DPN) is the most common microvascular complication of diabetes that affects approximately half of the diabetic population. Up to 53% of DPN patients experience neuropathic pain, which leads to a reduction in the quality of life and work productivity. Tocotrienols have been shown to possess antioxidant, anti-inflammatory, and neuroprotective properties in preclinical and clinical studies. This study aimed to investigate the effects of tocotrienol-rich vitamin E (Tocovid SuprabioTM) on nerve conduction parameters and serum biomarkers among patients with type 2 diabetes mellitus (T2DM). A total of 88 patients were randomized to receive 200 mg of Tocovid twice daily, or a matching placebo for 12 months. Fasting blood samples were collected for measurements of HbA1c, renal profile, lipid profile, and biomarkers. A nerve conduction study (NCS) was performed on all patients at baseline and subsequently at 2, 6, 12 months. Patients were reassessed after 6 months of washout. After 12 months of supplementation, patients in the Tocovid group exhibited highly significant improvements in conduction velocity (CV) of both median and sural sensory nerves as compared to those in the placebo group. The between-intervention-group differences (treatment effects) in CV were 1.60 m/s (95% CI: 0.70, 2.40) for the median nerve and 2.10 m/s (95% CI: 1.50, 2.90) for the sural nerve. A significant difference in peak velocity (PV) was also observed in the sural nerve (2.10 m/s
95% CI: 1.00, 3.20) after 12 months. Significant improvements in CV were only observed up to 6 months in the tibial motor nerve, 1.30 m/s (95% CI: 0.60, 2.20). There were no significant changes in serum biomarkers, transforming growth factor beta-1 (TGFβ-1), or vascular endothelial growth factor A (VEGF-A). After 6 months of washout, there were no significant differences from baseline between groups in nerve conduction parameters of all three nerves. Tocovid at 400 mg/day significantly improve tibial motor nerve CV up to 6 months, but median and sural sensory nerve CV in up to 12 months of supplementation. All improvements diminished after 6 months of washout.
Databáze: OpenAIRE
Externí odkaz: